Welcome to our dedicated page for Guardant Health news (Ticker: GH), a resource for investors and traders seeking the latest updates and insights on Guardant Health stock.
Guardant Health, Inc. develops precision oncology diagnostics and data products centered on blood and tissue testing for cancer care. Company news commonly covers the Guardant360 liquid biopsy and Guardant360 Tissue franchises, Guardant Reveal for molecular residual disease monitoring, Shield colorectal cancer screening, and InfinityAI real-world data and analytics.
Recurring updates include financial results across Oncology, Screening, and Biopharma & Data revenue categories; FDA companion diagnostic approvals for Guardant360 CDx; research presentations in tumor typing, therapy selection, methylation and multiomic testing; and biopharma collaborations that use Guardant tissue and liquid biopsy assays to support targeted therapy development.
Guardant Health has announced a collaboration with AstraZeneca to develop the Guardant360 CDx blood test as a companion diagnostic for ESR1-mutated metastatic breast cancer. This initiative is part of a strategic partnership to leverage liquid biopsy for early therapy interventions. The Guardant360 CDx test will identify patients with detectable ESR1 mutations during the SERENA-6 phase III clinical trial, evaluating camizestrant. The collaboration aims to improve patient outcomes through early detection and intervention.
Guardant Health (Nasdaq: GH) has announced that new data from its blood tests will be presented at the 2022 San Antonio Breast Cancer Symposium from December 6-10. The presentations will showcase the Guardant360® blood test and the GuardantINFORM™ dataset, focusing on critical biomarkers and treatment patterns in advanced breast cancer. Guardant aims to demonstrate the utility of its tests in enhancing understanding of biomarker targets and therapy responses, potentially leading to improved patient outcomes.
Guardant Health, Inc. (Nasdaq: GH) reported its Q3 2022 financial results, achieving $117.4 million in revenue, a 24% year-over-year increase. Clinical testing volumes surged 42% and biopharma sample volumes rose 40% compared to Q3 2021. Despite this growth, the company experienced a net loss of $162 million, a significant increase from $107.5 million the previous year. Operating expenses also rose 29% to $221.5 million. Due to ongoing challenges, the revenue guidance for 2022 has been revised down to $440-$450 million.
Guardant Health, Inc. (NASDAQ: GH) announced it will release its third quarter 2022 financial results on November 3, 2022, after market close. The company will host a webcast conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results. Investors can listen live through the company's website, with an archived replay available post-event. Guardant Health focuses on precision oncology and offers a variety of proprietary tests aimed at improving patient outcomes and reducing healthcare costs.
Guardant Health (NASDAQ: GH) has launched GuardantINFINITY™, a next-generation liquid biopsy assay that enhances tumor analysis by combining over 800 gene panel insights with exome-wide methylation detection. This innovative platform allows researchers to gain comprehensive insights into tumor biology and patient immune responses through a simple blood draw, eliminating the need for further sample collection. The assay supports various applications, including therapy selection and monitoring, marking a significant advancement in precision oncology.
Guardant Health (Nasdaq: GH) announced new data from its blood tests to be presented at the 2022 ESMO Congress (September 9-13, Paris). It includes findings on liquid biopsy tests to identify biomarkers, predict therapy response, and detect resistance mechanisms in late-stage cancers. Highlights involve oral and poster presentations showcasing significant findings like genomic resistance mechanisms and clinical potential of ctDNA for monitoring treatments. These advancements aim to foster better understanding and outcomes in cancer therapy.
Guardant Health (Nasdaq: GH) has announced an expanded collaboration with Merck KGaA to advance precision oncology through its GuardantINFORM real-world evidence platform. This partnership aims to speed up therapy development for crucial cancer indications with high unmet needs. Data scientists from Guardant Health will work alongside Merck KGaA on various initiatives using genomic and clinical information from over 225,000 cancer patients. This collaboration emphasizes Guardant Health's commitment to improving patient outcomes and accelerating the availability of innovative cancer treatments.
Guardant Health, a precision oncology leader, will participate in the Morgan Stanley Global Healthcare Conference in New York City on September 12, at 8:10 a.m. ET. The event will include a fireside chat, accessible via a live and archived webcast on the company’s website. Guardant Health specializes in cancer diagnostics, leveraging proprietary tests like the Guardant360 and Guardant Reveal to enhance patient outcomes and reduce healthcare costs. Visit guardanthealth.com for more information.
Guardant Health Inc. (Nasdaq: GH) has expanded the availability of its innovative blood test, Guardant Reveal™, which detects minimal residual disease in colorectal, breast, and lung cancers without the need for a tissue biopsy. This test enables early identification of patients at higher risk for recurrence post-surgery, promising improved management of early-stage cancer. The Guardant Reveal test can be initiated three weeks post-surgery and outperforms traditional monitoring tools in predicting disease recurrence.
Guardant Health has received FDA approval for its Guardant360 CDx liquid biopsy test as a companion diagnostic for patients with unresectable or metastatic HER2-mutant non-small cell lung cancer (NSCLC). This test identifies patients who may benefit from the antibody drug conjugate ENHERTU. The Guardant360 CDx assay will enable oncologists to obtain comprehensive genomic results from a blood sample within a week, marking a significant advancement over traditional tissue biopsies. The HER2 mutations drive 2-4% of non-squamous NSCLC, representing a critical step for targeted cancer therapies.